Antonio Di Meglio
A5025683264- Cancer survivorship and care
- Cancer-related cognitive impairment studies
- Cancer Risks and Factors
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Global Cancer Incidence and Screening
- Childhood Cancer Survivors' Quality of Life
- BRCA gene mutations in cancer
- Nutrition and Health in Aging
- Family Support in Illness
- Multiple and Secondary Primary Cancers
- Metabolism, Diabetes, and Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Estrogen and related hormone effects
- Neutropenia and Cancer Infections
- Cancer Genomics and Diagnostics
- Lymphatic System and Diseases
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Reproductive Biology and Fertility
- Palliative Care and End-of-Life Issues
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Prostate Cancer Treatment and Research
- Medication Adherence and Compliance
Institut Gustave Roussy
2018-2025
Inserm
2018-2025
Université Paris-Saclay
2018-2024
Prédicteurs moléculaires et nouvelles cibles en oncologie
2020-2024
Predict (France)
2022-2024
Target (United States)
2021
Dana-Farber Cancer Institute
2016-2021
Ospedale Policlinico San Martino
2013-2020
Centre Léon Bérard
2019
Centre Oscar Lambret
2019
Nonadherence to long-term treatments is often under-recognized by physicians and there no gold standard for its assessment. In breast cancer, nonadherence tamoxifen therapy after surgery constitutes a major obstacle optimal outcomes. We sought evaluate the rate of biochemical adjuvant using serum assessment examine effects on short-term, distant disease-free survival (DDFS).We studied 1,177 premenopausal women enrolled in large prospective study (CANTO/NCT01993498). Definition was based...
Adverse effects of breast cancer treatment can negatively affect survivors' work ability. Previous reports lacked detailed clinical data or health-related patient-reported outcomes (PROs) and did not prospectively assess the combined impact related sequelae on employment.We used a French prospective cohort patients with stage I-III including 1,874 women who were working ≥ 5 years younger than legal retirement age (≤ 57 years) at diagnosis. Our outcome was nonreturn to (non-RTW) 2 after...
We aimed to characterize long-term quality of life (QOL) trajectories among patients with breast cancer treated adjuvant chemotherapy and identify related patterns health behaviors.Female stage I-III receiving in CANTO (CANcer TOxicity; ClinicalTrials.gov identifier: NCT01993498) were included. Trajectories QOL (European Organisation for Research Treatment Cancer Quality Life Questionnaire-C30 Summary Score) associations trajectory group membership identified by iterative estimations...
PURPOSE Fatigue is common and troublesome among breast cancer survivors; however, limited tools exist to predict its risk. PATIENTS AND METHODS Participants with stage I-III were prospectively included from CANTO (ClinicalTrials.gov identifier: NCT01993498 ), collecting longitudinal data at diagnosis (before the initiation of any treatment) 1 (T1), 2 (T2), 4 (T3) years after diagnosis. The main outcome was severe global fatigue T2 (score ≥ 40/100, European Organisation for Research Treatment...
Importance Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy survivors included limited data BRCA carriers. Objective To investigate cumulative incidence disease-free survival young are Design, Setting, Participants International, multicenter, hospital-based, retrospective cohort study conducted at 78 participating centers worldwide. The...
Abstract Background Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) BRCA1/2 genes is infrequent but often associated with aggressive features. Human epidermal growth factor receptor 2 (HER2)‐low‐expressing BC has recently emerged as a novel therapeutic target not been characterized this rare patient subset. Methods Women newly diagnosed early‐stage HER2‐negative (HER2‐0 and HER2‐low) PVs from 78 health care centers worldwide were retrospectively...
Background In patients treated with cardiotoxic chemotherapies, the presence of cardiovascular risk factors and previous cardiac disease have been strongly correlated to onset cardiotoxicity. The influence overweight obesity as in development treatment-related cardiotoxicity breast cancer (BC) was recently suggested. However, due meta-analysis design, it not possible take into account associated or other classic for anthracycline (antineoplastic antibiotic) trastuzumab (monoclonal antibody)...
PURPOSE Fatigue is recognized as one of the most burdensome and long-lasting adverse effects cancer treatment. We aimed to characterize long-term fatigue trajectories among breast survivors. METHODS performed a detailed longitudinal analysis using large ongoing national prospective clinical study (CANcer TOxicity, ClinicalTrials.gov identifier: NCT01993498 ) patients with stage I-III treated from 2012 2015. was assessed at diagnosis year 1, 2, 4 postdiagnosis. Baseline clinical,...
<h3>Importance</h3> Breast cancer (BC) diagnosis and treatment expose patients to a 5-fold higher risk of depression compared with the general population, an estimated prevalence 10% 25%. A depressive episode in BC has implications for tolerance adherence treatment, impairing quality life reducing expectancy. <h3>Objective</h3> To identify characterize distinct longitudinal patterns symptoms from 3 years after treatment. <h3>Design, Settings, Participants</h3> The CANTO-DEePRESS (Deeper...
PURPOSE Socioeconomic status (SES) influences the survival outcomes of patients with early breast cancer (EBC). However, limited research investigates social inequalities in their quality life (QoL). This study examines socioeconomic QoL after an EBC diagnosis and time trends. PATIENTS AND METHODS We used data from French prospective multicentric CANTO cohort (ClinicalTrials.gov identifier: NCT01993498 ), including women enrolled between 2012 2018. was assessed using European Organisation...
Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its impact prognosis of young patients harboring pathogenic variant (PV) the BRCA1 and/or BRCA2 genes.
•Sexual concerns are frequent at BC diagnosis and seem to increase or persist in the after-treatment period.•Less than 50% of patients with reported sexual consulted proper supportive care specialists.•This large longitudinal cohort study helps identify that more likely report persistent concerns.•A proactive evaluation management health must exist across continuum. BackgroundSexual a major unaddressed need among survivors breast cancer (BC) significant negative effects on quality life. We...
Abstract Purpose A substantial proportion of cancer survivors experience fatigue after diagnosis. Physical activity (PA) can impact cancer. In this study, we evaluated the prevalence and association practice PA in a population with early Methods Using national population‐based French cross‐sectional study Vie après le 2 , included 1984 patients breast (61.1%), prostate (21.5%), colorectal (17.4%) Severe at years postdiagnosis was defined by score ≥40 European Organization for Research...
Abstract Young breast cancer (BC) patients carrying a germline BRCA pathogenic variant ( mBRCA ) have similar outcomes as non-carriers. However, the impact of type gene BRCA1 vs. BRCA2 and hormone receptor status (positive [HR+] negative [HR−]) on clinical behavior BC remains largely unknown. This is an international, multicenter, hospital-based, retrospective cohort study that included diagnosed, between January 2000 December 2012, with stage I–III invasive early at age ≤40 years. From 30...
Importance Younger survivors of breast cancer frequently report more treatment-related symptoms, mostly related to the menopausal transition. Objective To assess factors associated with chemotherapy-related amenorrhea (CRA) and evaluate its association long-term quality life (QOL). Design, Setting, Participants The prospective, longitudinal Cancer Toxicities Study, a multicenter French cohort study, includes women diagnosis stage I III collects data approximately yearly after diagnosis....
PURPOSE Optimal comprehensive survivorship care is insufficiently delivered. To increase patient empowerment and maximize the uptake of multidisciplinary supportive strategies to serve all needs, we implemented a proactive pathway for patients with early breast cancer at end primary treatment phase. METHODS Pathway components included (1) personalized plan (SCP), (2) face-to-face education seminars consultation referrals (Transition Day), (3) mobile app delivering self-management advice, (4)...
Abstract Background Inflammation could be related to cancer-related cognitive impairment (CRCI) and might used as a predictive marker of long-term CRCI. We evaluated associations between inflammatory markers assessed at diagnosis breast cancer CRCI two years afterwards. Methods Newly diagnosed stage I-III patients with from the French CANTO-Cog (Cognitive sub-study CANTO, NCT01993498) were included (baseline). Serum (IL-2, IL-4, IL-6, IL-8, IL-10, TNFα, CRP) baseline. Outcomes year 2...
BackgroundWe aimed to generate a model of cancer-related fatigue (CRF) clinical importance two years after diagnosis breast cancer building on and behavioral factors integrating pre-treatment markers systemic inflammation.MethodsWomen with stage I-III HR+/HER2- were included from the multimodal, prospective CANTO cohort (NCT01993498). The primary outcome was global CRF (EORTC QLQ-C30≥40/100) (year-2). Secondary outcomes physical, emotional, cognitive QLQ-FA12). All candidate variables...
Background This study assessed the prevalence and risk factors of unhealthy behaviors among survivors early‐stage breast cancer. Methods Women (n = 9556) from CANcer TOxicity cohort (NCT01993498) were included. Physical activity (PA), tobacco alcohol consumption, body mass index at diagnosis years 1 2 after diagnosis. A behavior was defined as if patients failed to meet PA recommendations (≥10 metabolic equivalent task hours per week), reduce/quit tobacco, or decrease consumption less than...